Share Issue/Capital Change • Jan 31, 2019
Share Issue/Capital Change
Open in ViewerOpens in native device viewer
Contact persons: SE-751 03 Uppsala Torben Jörgensen, CEO Tel:+ 46 18 56 59 00 Tel: +46 707 49 05 84, [email protected] www.biotage.com Erika Söderberg Johnson, CFO Tel: +46 707 20 48 20, [email protected]
Box 8
Uppsala January 31, 2019
As previously announced, Biotage AB (publ) (Biotage) has during January 2019 issued 487,337 new shares in connection with the acquisition of PhyNexus, Inc.
Prior to the issue, the total number of outstanding shares and votes in Biotage was 64,714,447. Through the issue the number of shares in Biotage increased by 487,337, corresponding to 487,337 votes. Today, the last trading day of the month, the total number of shares and votes in Biotage is 65,201,784.
This is information that Biotage AB (publ) is obliged to make public pursuant to the Swedish Financial Instruments Trading Act. The information was submitted for publication, through the agency of the contact persons set out above, at 08:30CET on January 31, 2019.
Biotage offers efficient separation technologies from analysis to industrial-scale and high-quality solutions for analytical chemistry from research to commercial analysis laboratories. Biotage's products are used by public authorities, academic institutions, contract research and contract manufacturing organizations and in the pharmaceutical and food industries, among others. The company is headquartered in Uppsala and has offices in the US, UK, China, Japan, South Korea and India. Biotage has approx. 410 employees and had sales of 748 MSEK in 2017. Biotage is listed on Nasdaq Stockholm. Website: www.biotage.com
Building tools?
Free accounts include 100 API calls/year for testing.
Have a question? We'll get back to you promptly.